KATNA1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29176296	1.00	1/20
SCHEMBL30800072	1.00	1/20
SCHEMBL29176303	0.82	1/20
SCHEMBL30799984	0.82	1/20
SCHEMBL29176274	0.80	1/20
SCHEMBL29176277	0.80	1/20
SCHEMBL30800000	0.80	1/20
SCHEMBL30800011	0.80	1/20
SCHEMBL28478712	0.78	1/20
SCHEMBL29176271	0.73	1/20
SCHEMBL29176281	0.64	1/20
SCHEMBL30800023	0.64	1/20
SCHEMBL30800070	0.62	1/20
SCHEMBL19207479	0.54	1/20
SCHEMBL29176273	0.54	1/20
SCHEMBL30799997	0.54	1/20
SCHEMBL28477323	0.53	1/20
SCHEMBL29176302	0.52	1/20
SCHEMBL30800001	0.52	1/20
SCHEMBL28477773	0.52	1/20

Clinical trials — most relevant to KATNA1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients	PHASE1/PHASE2	COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder	PHASE2	WITHDRAWN
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Pediatric Reporting of Adult-Onset Genomic Results	EARLY_PHASE1	COMPLETED
Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia	nan	RECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)	nan	COMPLETED
PCD New Gene Discovery	nan	COMPLETED
Clinical and Genetic Examinations of Dilated Cardiomyopathy	nan	COMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Structural Validity and Inter-rater Reliabitiliy of the Ataxia Trunk, Lower And Upper Extremity Scale (ATLAS)	nan	NOT_YET_RECRUITING
New Strategies of Genetic Study of Patients With Oculocutaneous Albinism	nan	COMPLETED
Collection of Blood Samples for DNA in Motor Neuron Disease	nan	COMPLETED
Diagnosis of Primary Ciliary Dyskinesia	nan	COMPLETED
Phenotype/Genotype Correlations in Neuromuscular Disorders	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions	nan	RECRUITING
Genetic Study of Patients With Primary Ciliary Dyskinesia	nan	COMPLETED
Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry	nan	NOT_YET_RECRUITING
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation	nan	RECRUITING
Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis.	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KATNA1 binder may also engage these)

Protein	Name	Similarity
Q4R407	—	1.000	Q4R407 →
Q9WV86	—	1.000	Q9WV86 →
Q6E0V2	—	1.000	Q6E0V2 →
Q0IIR9	—	1.000	Q0IIR9 →
B5X3X5	—	1.000	B5X3X5 →
Q5RII9	—	1.000	Q5RII9 →
Q9PUL2	—	1.000	Q9PUL2 →
Q1HGK7	—	1.000	Q1HGK7 →
Q8K0T4	—	1.000	Q8K0T4 →
Q5U3S1	—	1.000	Q5U3S1 →
A9RA82	—	1.000	A9RA82 →
Q9BW62	—	0.999	Q9BW62 →
B3EX35	—	0.999	B3EX35 →
O15381	—	0.997	O15381 →
Q9DBY8	—	0.997	Q9DBY8 →
Q9SEX2	—	0.997	Q9SEX2 →
Q6NW58	—	0.996	Q6NW58 →
Q3B8D5	—	0.996	Q3B8D5 →
Q05AS3	—	0.996	Q05AS3 →
B2RYN7	—	0.995	B2RYN7 →
A0JMA9	—	0.995	A0JMA9 →
P54778	—	0.995	P54778 →
Q8SRH0	—	0.994	Q8SRH0 →
O61577	—	0.994	O61577 →
KATNAL2	Katanin p60 ATPase-containing subunit A-like 2	0.994	landscape →
Q6AZT2	—	0.994	Q6AZT2 →
B4NBB0	—	0.994	B4NBB0 →
Q8LQJ9	—	0.993	Q8LQJ9 →
Q9H1H9	—	0.993	Q9H1H9 →
Q5ZK92	—	0.993	Q5ZK92 →